For research use only. We do not sell to patients.
Research lipid catalog

Ionizable Lipid Products

Explore 848 lipid and RNA delivery products. Search the full catalog or browse by research category.

Search covers product name, catalog number, synonyms, available CAS numbers and categories. Spaces, hyphens and common punctuation are ignored. Duplicate legacy records are consolidated under one canonical product result.

7177 products · Showing 6921–6940 · 20 per page
DC Chemicals lipid expertise

Built for ionizable-lipid discovery and RNA delivery research

DC Chemicals supports formulation and delivery research with a broad, searchable portfolio of cationic and ionizable lipids. The current directory brings together 848 unique research-use products, with product specifications, pricing, chemical structures and literature-linked formulation data added as each record is verified.

Our experience spans complex lipid synthesis, purification, analytical release and process development. For custom molecules or larger-scale requirements, our team can discuss route development, technical specifications and scale-up options for the intended research workflow.

Learn about cationic and ionizable lipids →
848unique products in the current searchable directory
Evidence-awareliterature modules appear only after source review
Research supportformulation context, handling guidance and calculators
Proprietary innovation · Co-development · GMP

From proprietary lipid design to GMP-grade custom synthesis

DC Chemicals has independently developed ionizable-lipid structures supported by company-owned intellectual property, and selected proprietary lipid programs have advanced to GMP-stage development.

We welcome joint development with customers—from molecular design and lipid synthesis through route and process development. We can also support custom synthesis of GMP-grade ionizable lipids to agreed technical specifications and quality requirements.

Discuss a co-development project →
Proprietary ionizable-lipid structuresCollaborative molecular designCustom lipid synthesisProcess development and scale-upGMP-grade project support

Cat. No.Product NameField of ApplicationChemical Structure
AzimilideFeatured

A class ΙΙΙ antiarrhythmic agent that blocks hERG channel; blocks HERG channel at 0.1 and 1 Hz with IC50s of 1.4 uM and 5.2 uM respectively; blocks the rapidly activating component of the delayed rectifier, IKr (IC50=0.4 uM), and inhibits IKs (IC50=3 uM); shows anti-arrhythmic effects.Heart ArrhythmiaPhase 3 Clinical

Azimilide

A glycolytic inhibitor that inhibits hexokinase II activity, suppresses ATP production, and induces endoplasmic reticulum (ER) stress; potentiates acetate-induced apoptosis and anti-proliferative effect in CRC cells; abrogates MUC1-mediated radiation resistance both in vitro and in vivo pancreatic cancer models, by reducing glucose flux into nucleotide biosynthetic pathways and enhancing DNA damage.

3-Bromopyruvic acid

A melatonin receptor agonist of MT1 (Ki=0.1nM) and MT2 (Ki=0.12nM), and a 5-HT2C (Ki=631nM) receptor antagonist; has no effect on monoamine uptake and no affinity for adrenergic, histaminergic, cholinergic, dopaminergic and benzodiazepine receptors, nor other serotonergic receptors; a melatonergic antidepressant treatment of major depressive disorder with relatively favorable side effect profile.DepressionApproved

Agomelatine hydrochloride

A potent and selective JAK1/JAK2 inhibitor with IC50 of 11/18 nM; shows significantly less activity against other kinases, including JAK3 (IC50=155 nM); inhibits JAK2V617F (JH1-JH2) withIC50 of 11 nM; inhibits growth of Ba/F3-JAK2V617F and HEL cells (IC50=1500 nM) or Ba/F3-MPLW515L cells (IC50=200 nM). Bone CancerPhase 3 Clinical

CYT387 sulfate salt

In Vitro Dibutyl phthalate (0.001 µg/mL-1000 µg/mL) is detrimental to follicle growth and viability and results in significant dysregulation of cell cycle and apoptosis gene expression in a dose-specific manner. But MBP does not play a role in Dibutyl phthalate toxicity in follicles exposed in vitro. In Vivo Dibutyl phthalate (200, 400, or 600 mg/kg/day) induces decrease mice weight, impairment of spermatogenesis, reduces serum follicle stimulating hormone and testosterone level, alters testicular LDH, increases LPO, and decreases the levels of enzymatic antioxidants with histopathological anomalies. Dibutyl phthalate (6.25, 12.5, 25, 50, 100 and 200 mg/kg) could cause some neurobehavioral adverse effects in mice.

Dibutyl phthalate

Erlotinib (CP-358774;OSI-774;NSC 718781) is a potent, selective inhibitor of EGFR with IC50 of 2 nM; reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM; inhibits the proliferation of DiFi human colon tumor cells at submicromolar concentrations in cell culture and blocks cell cycle progression at the G1 phase; 100mg/kg completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice; orally active.Lung CancerApproved

Erlotinib mesylate

Quizartinib (AC220) is a potent, selective, second-generation FLT3 inhibitor with Kd of 1.6 nM, inhibits Wt FLT3 and FLT3-ITD autophosphorylation in MV4-11cell with IC50 of 4.2 and 1.1 nM, respectively; displays excellent kinase selectivity in a KinomeScan panel of 402 kinase binding assays, also potently inhibits PDGFRA, PDGFRB and RET; inhibits MV4-11 cell proliferarion with IC50 of 0.56 nM, demonstrates antitumor efficacy in the MV4-11 tumor xenograft model.Blood CancerPhase 3 Clinical

Quizartinib hydrochloride

A highly selective, non-ATP competitive substrate-pocket-directed Src/pretubulin inhibitor; inhibits c-Src kinase with GI50s of 1.34 uM and 2.30 μM in NIH3T3/c-Src527F and SYF/c-Src527F cells, respectively; causes microtubule disruption in tumor cells; orally active.Solid TumorsPhase 2 Clinical

KX2-391 dihydrochloride
OB-24Featured

OB-24 is a potent inhibitor of heme oxygenase-1 (HO-1). Heme oxygenase-1, a member of the heat shock protein family, plays a key role as a sensor and regulator of oxidative stress. OB-24 significantly inhibited cell proliferation in vitro and tumor growth and lymph node/lung metastases in vivo. OB-24 has potential for the research of advanced prostate cancer (PCA).

OB-24

DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC50 of 80 nM.

DMPQ dihydrochloride
B-Raf IN 14Featured

B-Raf IN 14 (Comp 25) is a BRAF inhibitor with IC50 value of 11.08 μM, which can be used in cancer-related research.

B-Raf IN 14
MMP-9-IN-7Featured

MMP-9-IN-7 is a potent MMP9 inhibitor with an IC50 of 0.52 μM in proMMP9/MMP3 P126 activation assay. MMP-9-IN-7 is extracted from patent WO2012162468 (example 59), and can be used for MMP9/MMP13 mediated syndrome research.

MMP-9-IN-7
PSB-1901Featured

PSB-1901 is a potent A2B adenosine receptor (A2BAR) antagonist with Kis of 0.0835 nM and 0.131 nM for human and mouse A2BARs respectively. PSB-1901 can be used for the research of cancer.

PSB-1901
ML261Featured

ML-261 is a thienopyrrole-5-carboxamide that inhibits lipid droplet formation.

ML261

Minoxidil sulfate, a potent and ATP-sensitive K+ channel opener, is the sulfated metabolite of minoxidil. Minoxidil sulfate is considered as a vasodilator to promote hair growth in vivo.

Minoxidil sulfate
GR-127935Featured

GR-127935 is a potent and selective 5-HT1B/1D receptor antagonist with pKi of 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptor; displays >100-fold selectivity over 5HT1A, 5-HT2A, 5-HT2C receptors and other receptor types; blocks porcine carotid vascular response to sumatriptan in vivo; orally bioavailable and centrally active.

GR-127935

Page 347 of 359 · Browse all 7177 products

Jump to a product page

Featured literature product: HX1 · DCL0028

HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied in lipid nanoparticles for brain mRNA delivery and CRISPR–Cas9 delivery. It was the lead in the reported in vivo brain-delivery screen; evidence is preclinical and formulation-dependent.

Read full formulation and performance →